Literature DB >> 2801340

An investigation into the possible involvement of platelet activating factor in experimental allergic encephalomyelitis in rats.

D W Howat1, N Chand, P Braquet, D A Willoughby.   

Abstract

Rats developing experimental allergic encephalomyelitis have been treated with intra-venous injections of Platelet-Activating Factor on days 5, 6 and 7 post adjuvant injection. Other rats have been treated with one of two different PAF antagonists or vehicle. The animals injected with PAF on day 5 post adjuvant developed a more severe form of the disease at an earlier time point than did control animals. Animals treated with the PAF antagonists did not develop the disease to any great extent. Treatment with the vehicle had no effect compared to control. These results implicate PAF in the aetiology of this model of multiple sclerosis and may suggest a role for PAF antagonists in the treatment of this disease.

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2801340     DOI： 10.1007/bf01972856

Source DB:  PubMed          Journal:  Agents Actions        ISSN： 0065-4299


  12 in total

1.  A histologic study of the early lesion in experimental allergic encephalomyelitis in the guinea pig and rabbit.

Authors:  B H WAKSMAN; R D ADAMS
Journal:  Am J Pathol       Date:  1962-08       Impact factor: 4.307

2.  Brain vascular permeability to I-125 gamma globulin and leukocytes in allergic encephalomyelitis.

Authors:  R W Cutler; A V Lorenzo; C F Barlow
Journal:  J Neuropathol Exp Neurol       Date:  1967-10       Impact factor: 3.685

Review 3.  Perspectives in platelet-activating factor research.

Authors:  P Braquet; L Touqui; T Y Shen; B B Vargaftig
Journal:  Pharmacol Rev       Date:  1987-06       Impact factor: 25.468

4.  Blood-cerebrospinal fluid barrier permeability changes in guinea pigs inoculated for chronic relapsing experimental allergic encephalomyelitis or with adjuvant alone.

Authors:  A J Suckling; H Reiber; J A Kirby; M G Rumsby
Journal:  Prog Clin Biol Res       Date:  1984

5.  Changes in the effectiveness of the blood-brain and blood-spinal cord barriers in experimental allergic encephalomyelitis.

Authors:  P M Daniel; D K Lam; O E Pratt
Journal:  J Neurol Sci       Date:  1981 Nov-Dec       Impact factor: 3.181

6.  Chronic relapsing experimental allergic encephalomyelitis. Immunological and blood--cerebrospinal fluid barrier-dependent changes in the cerebrospinal fluid.

Authors:  A J Suckling; H Reiber; J A Kirby; M G Rumsby
Journal:  J Neuroimmunol       Date:  1983-02       Impact factor: 3.478

7.  Neuropathology of experimental allergic encephalomyelitis in inbred strains of mice.

Authors:  C S Raine; L B Barnett; A Brown; T Behar; D E McFarlin
Journal:  Lab Invest       Date:  1980-08       Impact factor: 5.662

8.  Retinal venous sheathing in optic neuritis. Its significance for the pathogenesis of multiple sclerosis.

Authors:  S Lightman; W I McDonald; A C Bird; D A Francis; A Hoskins; J R Batchelor; A M Halliday
Journal:  Brain       Date:  1987-04       Impact factor: 13.501

9.  Inhibition of human lymphocyte proliferation and interleukin 2 production by platelet activating factor (PAF-acether): reversal by a specific antagonist, BN 52021.

Authors:  M Rola-Pleszczynski; B Pignol; C Pouliot; P Braquet
Journal:  Biochem Biophys Res Commun       Date:  1987-02-13       Impact factor: 3.575

10.  Involvement of platelet-activating factor (PAF) in cerebral post-ischemic phase in Mongolian gerbils.

Authors:  B Spinnewyn; N Blavet; F Clostre; N Bazan; P Braquet
Journal:  Prostaglandins       Date:  1987-09
View more
  5 in total

1.  Professor Derek Albert Willoughby (1930-2004).

Authors:  K D Rainsford
Journal:  Inflammopharmacology       Date:  2005       Impact factor: 4.473

Review 2.  PAF. A review of its effects, antagonists and possible future clinical implications (Part II).

Authors:  M Koltai; D Hosford; P Guinot; A Esanu; P Braquet
Journal:  Drugs       Date:  1991-08       Impact factor: 9.546

3.  Role of platelet activating factor in the pathogenesis of active and passive models of experimental allergic encephalomyelitis in the rat.

Authors:  S Desai; R Barton
Journal:  Agents Actions       Date:  1990-08

4.  Effect of the leukotriene B4 receptor antagonist, SC-41930, on experimental allergic encephalomyelitis (EAE) in the guinea pig.

Authors:  D J Fretland; D L Widomski; R L Shone; S Levin; T S Gaginella
Journal:  Agents Actions       Date:  1991-09

5.  Dual phase regulation of experimental allergic encephalomyelitis by platelet-activating factor.

Authors:  Yasuyuki Kihara; Satoshi Ishii; Yoshihiro Kita; Akiko Toda; Atsuyoshi Shimada; Takao Shimizu
Journal:  J Exp Med       Date:  2005-09-19       Impact factor: 14.307
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.